{
  "study_id": "NCT01958021",
  "study_title": "Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer",
  "table_name": "Table 1",
  "table_title": "Characteristics of the Patients at Baseline.",
  "footnotes": [
    "There were no significant differences between the groups. ECOG denotes Eastern Cooperative Oncology Group.",
    "Race was self-reported.",
    "Some patients received both chemotherapy and endocrine therapy as neoadjuvant or adjuvant treatment.",
    "Visceral involvement included liver, lung, and other visceral metastases."
  ],
  "groups": [
    {
      "name": "Ribociclib Group",
      "n": 334
    },
    {
      "name": "Placebo Group",
      "n": 334
    }
  ],
  "characteristics": [
    {
      "original_label": "Median age (range) — yr",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "numeric_median_iqr",
          "median": 62.0,
          "iqr_min": 23.0,
          "iqr_max": 91.0,
          "raw_string": "62 (23-91)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "numeric_median_iqr",
          "median": 63.0,
          "iqr_min": 29.0,
          "iqr_max": 88.0,
          "raw_string": "63 (29-88)"
        }
      ]
    },
    {
      "original_label": "Race — no. (%)†",
      "standardized_name": "Race",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo Group",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "White",
      "standardized_name": "Race, White",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race — no. (%)†",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 269.0,
          "percentage": 80.5,
          "raw_string": "269 (80.5)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 280.0,
          "percentage": 83.8,
          "raw_string": "280 (83.8)"
        }
      ]
    },
    {
      "original_label": "Asian",
      "standardized_name": "Race, Asian",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race — no. (%)†",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 28.0,
          "percentage": 8.4,
          "raw_string": "28 (8.4)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 23.0,
          "percentage": 6.9,
          "raw_string": "23 (6.9)"
        }
      ]
    },
    {
      "original_label": "Black",
      "standardized_name": "Race, Black",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race — no. (%)†",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 10.0,
          "percentage": 3.0,
          "raw_string": "10 (3.0)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 7.0,
          "percentage": 2.1,
          "raw_string": "7 (2.1)"
        }
      ]
    },
    {
      "original_label": "Other or unknown",
      "standardized_name": "Race, Other or unknown",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race — no. (%)†",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 27.0,
          "percentage": 8.1,
          "raw_string": "27 (8.1)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 24.0,
          "percentage": 7.2,
          "raw_string": "24 (7.2)"
        }
      ]
    },
    {
      "original_label": "ECOG performance status — no. (%)",
      "standardized_name": "ECOG Performance Status",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo Group",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "0",
      "standardized_name": "ECOG Performance Status 0",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG performance status — no. (%)",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 205.0,
          "percentage": 61.4,
          "raw_string": "205 (61.4)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 202.0,
          "percentage": 60.5,
          "raw_string": "202 (60.5)"
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "ECOG Performance Status 1",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG performance status — no. (%)",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 129.0,
          "percentage": 38.6,
          "raw_string": "129 (38.6)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 132.0,
          "percentage": 39.5,
          "raw_string": "132 (39.5)"
        }
      ]
    },
    {
      "original_label": "Disease stage — no. (%)",
      "standardized_name": "Disease Stage",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo Group",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "III",
      "standardized_name": "Disease Stage III",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease stage — no. (%)",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.3,
          "raw_string": "1 (0.3)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 0.9,
          "raw_string": "3 (0.9)"
        }
      ]
    },
    {
      "original_label": "IV",
      "standardized_name": "Disease Stage IV",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease stage — no. (%)",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 333.0,
          "percentage": 99.7,
          "raw_string": "333 (99.7)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 331.0,
          "percentage": 99.1,
          "raw_string": "331 (99.1)"
        }
      ]
    },
    {
      "original_label": "Hormone-receptor status — no. (%)",
      "standardized_name": "Hormone Receptor Status",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo Group",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Estrogen-receptor positive",
      "standardized_name": "Estrogen Receptor Positive",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Hormone-receptor status — no. (%)",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 332.0,
          "percentage": 99.4,
          "raw_string": "332 (99.4)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 333.0,
          "percentage": 99.7,
          "raw_string": "333 (99.7)"
        }
      ]
    },
    {
      "original_label": "Progesterone-receptor positive",
      "standardized_name": "Progesterone Receptor Positive",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Hormone-receptor status — no. (%)",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 271.0,
          "percentage": 81.1,
          "raw_string": "271 (81.1)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 278.0,
          "percentage": 83.2,
          "raw_string": "278 (83.2)"
        }
      ]
    },
    {
      "original_label": "Disease-free interval — no. (%)",
      "standardized_name": "Disease-Free Interval",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo Group",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Newly diagnosed disease",
      "standardized_name": "Disease-Free Interval, Newly diagnosed disease",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease-free interval — no. (%)",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 114.0,
          "percentage": 34.1,
          "raw_string": "114 (34.1)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 113.0,
          "percentage": 33.8,
          "raw_string": "113 (33.8)"
        }
      ]
    },
    {
      "original_label": "Existing disease",
      "standardized_name": "Disease-Free Interval, Existing disease",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease-free interval — no. (%)",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 220.0,
          "percentage": 65.9,
          "raw_string": "220 (65.9)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 221.0,
          "percentage": 66.2,
          "raw_string": "221 (66.2)"
        }
      ]
    },
    {
      "original_label": "<12 mo",
      "standardized_name": "Disease-Free Interval, Existing disease <12 mo",
      "unit": "months",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Existing disease",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 1.2,
          "raw_string": "4 (1.2)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 10.0,
          "percentage": 3.0,
          "raw_string": "10 (3.0)"
        }
      ]
    },
    {
      "original_label": ">12 to ≤24 mo",
      "standardized_name": "Disease-Free Interval, Existing disease >12 to ≤24 mo",
      "unit": "months",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Existing disease",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 14.0,
          "percentage": 4.2,
          "raw_string": "14 (4.2)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 15.0,
          "percentage": 4.5,
          "raw_string": "15 (4.5)"
        }
      ]
    },
    {
      "original_label": ">24 mo",
      "standardized_name": "Disease-Free Interval, Existing disease >24 mo",
      "unit": "months",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Existing disease",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 202.0,
          "percentage": 60.5,
          "raw_string": "202 (60.5)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 195.0,
          "percentage": 58.4,
          "raw_string": "195 (58.4)"
        }
      ]
    },
    {
      "original_label": "Unknown",
      "standardized_name": "Disease-Free Interval, Existing disease, Unknown",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Existing disease",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "raw_string": "0"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.3,
          "raw_string": "1 (0.3)"
        }
      ]
    },
    {
      "original_label": "Previous treatment — no. (%)‡",
      "standardized_name": "Previous Treatment",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo Group",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Neoadjuvant or adjuvant chemotherapy",
      "standardized_name": "Neoadjuvant or Adjuvant Chemotherapy",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Previous treatment — no. (%)‡",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 146.0,
          "percentage": 43.7,
          "raw_string": "146 (43.7)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 145.0,
          "percentage": 43.4,
          "raw_string": "145 (43.4)"
        }
      ]
    },
    {
      "original_label": "Neoadjuvant or adjuvant endocrine therapy",
      "standardized_name": "Neoadjuvant or Adjuvant Endocrine Therapy",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Previous treatment — no. (%)‡",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 175.0,
          "percentage": 52.4,
          "raw_string": "175 (52.4)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 171.0,
          "percentage": 51.2,
          "raw_string": "171 (51.2)"
        }
      ]
    },
    {
      "original_label": "Anastrozole",
      "standardized_name": "Neoadjuvant or Adjuvant Endocrine Therapy, Anastrozole",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Neoadjuvant or adjuvant endocrine therapy",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 47.0,
          "percentage": 14.1,
          "raw_string": "47 (14.1)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 42.0,
          "percentage": 12.6,
          "raw_string": "42 (12.6)"
        }
      ]
    },
    {
      "original_label": "Exemestane",
      "standardized_name": "Neoadjuvant or Adjuvant Endocrine Therapy, Exemestane",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Neoadjuvant or adjuvant endocrine therapy",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 19.0,
          "percentage": 5.7,
          "raw_string": "19 (5.7)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 25.0,
          "percentage": 7.5,
          "raw_string": "25 (7.5)"
        }
      ]
    },
    {
      "original_label": "Goserelin",
      "standardized_name": "Neoadjuvant or Adjuvant Endocrine Therapy, Goserelin",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Neoadjuvant or adjuvant endocrine therapy",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 1.8,
          "raw_string": "6 (1.8)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 0.9,
          "raw_string": "3 (0.9)"
        }
      ]
    },
    {
      "original_label": "Letrozole",
      "standardized_name": "Neoadjuvant or Adjuvant Endocrine Therapy, Letrozole",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Neoadjuvant or adjuvant endocrine therapy",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 34.0,
          "percentage": 10.2,
          "raw_string": "34 (10.2)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 25.0,
          "percentage": 7.5,
          "raw_string": "25 (7.5)"
        }
      ]
    },
    {
      "original_label": "Tamoxifen",
      "standardized_name": "Neoadjuvant or Adjuvant Endocrine Therapy, Tamoxifen",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Neoadjuvant or adjuvant endocrine therapy",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 140.0,
          "percentage": 41.9,
          "raw_string": "140 (41.9)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 145.0,
          "percentage": 43.4,
          "raw_string": "145 (43.4)"
        }
      ]
    },
    {
      "original_label": "Other",
      "standardized_name": "Neoadjuvant or Adjuvant Endocrine Therapy, Other",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Neoadjuvant or adjuvant endocrine therapy",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 0.6,
          "raw_string": "2 (0.6)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 1.2,
          "raw_string": "4 (1.2)"
        }
      ]
    },
    {
      "original_label": "Metastatic sites — no. (%)",
      "standardized_name": "Number of Metastatic Sites",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo Group",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "0",
      "standardized_name": "Number of Metastatic Sites, 0",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Metastatic sites — no. (%)",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 0.6,
          "raw_string": "2 (0.6)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.3,
          "raw_string": "1 (0.3)"
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "Number of Metastatic Sites, 1",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Metastatic sites — no. (%)",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 100.0,
          "percentage": 29.9,
          "raw_string": "100 (29.9)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 117.0,
          "percentage": 35.0,
          "raw_string": "117 (35.0)"
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "Number of Metastatic Sites, 2",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Metastatic sites — no. (%)",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 118.0,
          "percentage": 35.3,
          "raw_string": "118 (35.3)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 103.0,
          "percentage": 30.8,
          "raw_string": "103 (30.8)"
        }
      ]
    },
    {
      "original_label": "≥3",
      "standardized_name": "Number of Metastatic Sites, ≥3",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Metastatic sites — no. (%)",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 114.0,
          "percentage": 34.1,
          "raw_string": "114 (34.1)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 113.0,
          "percentage": 33.8,
          "raw_string": "113 (33.8)"
        }
      ]
    },
    {
      "original_label": "Site of metastases — no. (%)",
      "standardized_name": "Site of Metastases",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Placebo Group",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Breast",
      "standardized_name": "Site of Metastases, Breast",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Site of metastases — no. (%)",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 8.0,
          "percentage": 2.4,
          "raw_string": "8 (2.4)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 11.0,
          "percentage": 3.3,
          "raw_string": "11 (3.3)"
        }
      ]
    },
    {
      "original_label": "Bone - Any",
      "standardized_name": "Site of Metastases, Bone, Any",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Site of metastases — no. (%)",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 246.0,
          "percentage": 73.7,
          "raw_string": "246 (73.7)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 244.0,
          "percentage": 73.1,
          "raw_string": "244 (73.1)"
        }
      ]
    },
    {
      "original_label": "Bone - Only",
      "standardized_name": "Site of Metastases, Bone, Only",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Site of metastases — no. (%)",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 69.0,
          "percentage": 20.7,
          "raw_string": "69 (20.7)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 78.0,
          "percentage": 23.4,
          "raw_string": "78 (23.4)"
        }
      ]
    },
    {
      "original_label": "Visceral§",
      "standardized_name": "Site of Metastases, Visceral",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Site of metastases — no. (%)",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 197.0,
          "percentage": 59.0,
          "raw_string": "197 (59.0)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 196.0,
          "percentage": 58.7,
          "raw_string": "196 (58.7)"
        }
      ]
    },
    {
      "original_label": "Lymph nodes",
      "standardized_name": "Site of Metastases, Lymph nodes",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Site of metastases — no. (%)",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 133.0,
          "percentage": 39.8,
          "raw_string": "133 (39.8)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 123.0,
          "percentage": 36.8,
          "raw_string": "123 (36.8)"
        }
      ]
    },
    {
      "original_label": "Other",
      "standardized_name": "Site of Metastases, Other",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Site of metastases — no. (%)",
      "group_data": [
        {
          "group_name": "Ribociclib Group",
          "data_type": "categorical_count_percentage",
          "count": 35.0,
          "percentage": 10.5,
          "raw_string": "35 (10.5)"
        },
        {
          "group_name": "Placebo Group",
          "data_type": "categorical_count_percentage",
          "count": 22.0,
          "percentage": 6.6,
          "raw_string": "22 (6.6)"
        }
      ]
    }
  ]
}
